Generics companies face risk as SCOTUS questions patent tribunal’s constitutionality

Generics companies face risk as SCOTUS questions patent tribunal’s constitutionality

Source: 
MedCity News
snippet: 

The U.S. Supreme Court heard oral arguments Monday on the constitutionality of the Patent Trial and Appeal Board, an essential piece of the United States patent litigation puzzle and favored tool of generic and biosimilar patent challengers since its formation in 2012.